Login to Your Account

GlycoVaxyn Finalizes Deal to Fund Bioconjugation Program

By Nuala Moran
Staff Writer

Friday, December 28, 2012
After landing the all-important validation of a deal with GlaxoSmithKline Biologicals (GSK) in December, GlycoVaxyn AG is expecting to finalize an agreement to fund development of its lead in-house program and seal further collaborations around its conjugated vaccine technology platform in 2013.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription